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Objectives: Cone beam computed tomography (CBCT), which provides a lower dose, lower cost
alternative to conventional CT, is being used with increasing frequency in the practice of oral and
maxillofacial radiology. This study provides comparative measurements of effective dose for three
commercially available, large (1200) field-of-view (FOV), CBCT units: CB Mercuray, NewTom 3G
and i-CAT.
Methods: Thermoluminescent dosemeters (TLDs) were placed at 24 sites throughout the layers of
the head and neck of a tissue-equivalent human skull RANDO phantom. Depending on availability,
the 1200 FOV and smaller FOV scanning modes were used with similar phantom positioning
geometry for each CBCT unit. Radiation weighted doses to individual organs were summed using
1990 (E1990) and proposed 2005 (E2005 draft) ICRP tissue weighting factors to calculate two measures
of whole-body effective dose. Dose as a multiple of a representative panoramic radiography dose
was also calculated.
Results: For repeated runs dosimetry was generally reproducible within 2.5%. Calculated doses in
mSv (E1990, E2005 draft) were NewTom3G (45, 59), i-CAT (135, 193) and CB Mercuray (477, 558).
These are 4 to 42 times greater than comparable panoramic examination doses (6.3 mSv, 13.3 mSv).
Reductions in dose were seen with reduction in field size and mA and kV technique factors.
Conclusions: CBCT dose varies substantially depending on the device, FOV and selected
technique factors. Effective dose detriment is several to many times higher than conventional
panoramic imaging and an order of magnitude or more less than reported doses for conventional CT.
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Introduction
Cone beam computed tomography (CBCT) provides a
lower dose, lower cost alternative to conventional CT that
promises to revolutionize the practice of oral and
maxillofacial radiology. CBCT has been used in an
expanding number of applications involving the disciplines
of endodontics,1 oral surgery,2,3 oral medicine,4,5 period-
ontology,6 restorative dentistry7 and orthodontics.8 With
the introduction of large (nominally 1200) imaging fields,
there has been a surge of interest in the use of CBCT as a
substitute for conventional panoramic and cephalometric
images for orthodontic treatment planning.
Although doses from CBCT are relatively low, patient
dose remains a concern in dental diagnostic imaging.9 The
possibility of a pituitary or thyroid link in the risk of low
birth weight infants due to maternal exposures to low levels
of dental X-ray is a recent example of a continuing scrutiny
of potential radiation hazards from diagnostic imaging.10
Increasing use of CBCT examinations means that more
patients are being subjected to the doses imparted from this
procedure. To the extent that CBCT is used as a substitute
for medical CT, patients will benefit from dose reduction.
However, in the case where CBCT is substituted for lower
dose conventional imaging alternatives, an increase in dose
detriment is imparted to the patient. In the instance of the
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child orthodontic patient this is of particular concern
because children are assumed to carry any radiation burden
for a longer period of time than adults and because
developing organs are more sensitive to radiation effects.
It is important for Oral and Maxillofacial Radiologists
to know and communicate the dose and associated risk of
specific examinations to their patients and referring
practitioners. It is critical for healthcare providers to
weigh the potential benefit of diagnostic information
against the expense and risk of the imaging procedure.
While early reports suggested that CBCT examination
doses were equivalent to a few panoramic exposures, these
reports were based on the unit of one vendor and a 900 field
of view (FOV).11,12 The current study provides compara-
tive measurements of effective dose for three commercially
available large (1200) FOV CBCT units. Thermolumines-
cent dosemeters (TLDs) positioned throughout the layers
of the head and neck of a tissue-equivalent RANDO
phantom were used to record doses from full field and,
when available, smaller field examinations. Average
tissue-absorbed dose, radiation weighted dose and effec-
tive dose were calculated. The radiation weighted dose,
formerly know by the terms dose equivalent and equivalent
dose was calculated following both International Commis-
sion on Radiological Protection (ICRP) 1990 tissue
weights13 and proposed 2005 tissue weights.14 Effective
doses from these calculations were used in relative
comparisons with conventional panoramic images and
annual per capita background dose.
Materials and methods
TLD chips were used to record the distribution of the
absorbed radiation dose at selected locations in the head
and neck region of a small adult skull and tissue-equivalent
phantom (RANDO – radiation analogue dosimetry
system; Nuclear Associates, Hicksville, NY) (Figure 1).
The 24 phantom sites measured in this study are listed in
Table 1. These locations reflect critical organs known to be
sensitive to radiation, along with the eyes and the pituitary
gland, which are sites of traditional and topical interest,
respectively, to dental imaging. An unexposed dosemeter
was also included for environmental calibration of each
technique run. Pre-calibrated 3 mm £ 3 mm £ 1 mm TLD
100 lithium fluoride chips were supplied and analysed by
Landauer Inc. (Landauer, Glenwood, IL). Landauer
calibrated each dosemeter by exposing it to a known
quantity of radiation from a Cs-137 source. Dosemeters
were analysed using an automatic hot gas reader and the
raw data were recorded. Individual TLD chip sensitivity
was obtained and applied as a correction factor to
subsequent exposure and reading of each TLD. The
standard deviation of calibrated readings from the supplied
TLD 100 chips is stated to be less than ^5%.
The CBCT units selected for this study were the CB
Mercuray (Hitachi Medical Systems America, Twinsburg,
OH), the NewTom 3G (QR, Verona, Italy) and the i-CAT
(Imaging Sciences International, Hatfield, PA). These units
were chosen for the large 1200 field of view (FOV) or beam
diameter produced at the surface of the image receptor.
This large FOV permits simultaneous imaging of the
complete base of the skull as well as maxillofacial anatomy
extending from the frontal process to the base of the chin.
This anatomic region is utilized in craniometric calcu-
lations for orthodontic diagnosis and treatment planning.
Full 1200 FOV examinations were conducted on the
RANDO phantom with each CBCT unit. Additional 900
and 600 FOV examinations were conducted with the CB
Mercuray and 900 FOV with the i-CAT. At the time this
research was conducted the NewTom 3G unit did not have
a smaller FOV imaging option. This unit currently has a 900
and 600 FOV as alternatives to the 1200 FOV. Both of these
units currently have these as available options. The
phantom was orientated in each unit such that the
phantom’s occlusal plane was parallel to the scan plane.
The midsagittal plane was centred in the image field and
Figure 1 Adult skull and tissue-equivalent phantom (RANDO). Levels
correspond to thermoluminescent dosemeter sites identified in Table 1
Table 1 Locations of thermoluminescent dosemeter (TLD) chips in
RANDO phantom
Organ Location Phantom level
Bone marrow Calvarium anterior 2
Calvarium left 2
Calvarium posterior 2
Centre cervical spine 6
Right/left mandible body 7
Right/left ramus 6
Brain Mid brain 2
Pituitary fossa 3
Eyes Right/left orbit 4
Right/left lens of eye 4
Salivary glands Right/left parotid 6
Right/left submandibular gland 7
Sublingual gland 7
Thyroid Thyroid surface 9
Midline thyroid 9
Skin Right cheek 5
Left back of neck 7
Oesophagus Pharyngeal-oesophageal space 9
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the soft tissue contours of the chin and nose were captured
at the margins of the field. Phantom levels 2–8 were
included in the full FOV examinations produced by each
unit. Midsagittal reconstructions resulting from these
examinations can be seen in Figure 2.
X-ray parameters of kV and mA are automatically
determined from scout views by the NewTom 3G.
Depending on the size of the patient and the extent of
beam attenuation a change in exposure of up to 40% is
possible. The exposure settings for the i-CAT are fixed
regardless of patient size. Technique factors of mA and kV
are operator adjustable for the CB Mercuray. Technique
factors of 120 kV and 15 mA were used in initial
examinations of the CB Mercuray. Using these factors
the CB Mercuray examination was repeated after 3 months
to determine examination reproducibility. Additional CB
Mercuray imaging at 100 kV and 10 mA was performed
when it was found that these settings produced subjectively
equivalent image quality for the phantom. Technical
factors for each unit can be seen in Table 2. Owing to
the relatively small amounts of radiation required for a
single examination in comparison with the exposure
latitude of the TLDs, multiple exposures for each radio-
graphic technique were utilized to provide a reliable
measure of radiation in the dosemeters. Three exposures
were made without changing the position of the phantom
for each CBCT examination variation.
Doses from TLDs at different positions within a tissue
or organ were averaged to express the average tissue-
absorbed dose in micrograys (mGy). The products of these
values and the percentage of a tissue or organ irradiated in
a full FOV exam (Table 3) were used to calculate the
radiation weighted dose (HT) in microsieverts (mSv).
13
For bone marrow, the radiation weighted dose to the
whole-body bone marrow is calculated using the
summation of the individual radiation weighted dose to
the calvarium, the mandible and the cervical spine. The
determination of these radiation weighted doses is based
on the distribution of active bone marrow throughout the
adult body: the mandible contains 1.3%, the calvaria
contains 11.8% and the cervical spine contains 3.4%.15
Following the technique of Underhill et al, three
locations within the calvarium were averaged to
determine calvarial dose.16
The proportion of skin surface area in the head and
neck region directly exposed by each technique was
estimated as 5% of the total body to calculate radiation
weighted dose to the skin following the procedure used
in a previous study.11 Similarly, muscle, adipose,
connective tissue and lymphatic nodes exposures were
estimated to represent 5% of the total body complement
for these tissues. The proportion of the oesophageal
tract that was exposed was conservatively set at 10%.
Effective dose (E) is a widely used calculation that
permits comparison of the detriment of different exposures to
ionizing radiation to an equivalent detriment produced by a
full body dose of radiation. E, expressed in mSv, was
calculated using the equation: E ¼ SwT £ HT, where E is the
product of the tissue weighting factor (wT), which represents
Table 2 Technical factors for standard full field of view (FOV) exposure
of RANDO phantom
CB Mercuray i-CAT NewTom 3G
kV 100 120 110
mA 10.0 5.7 1.5
Total exposure time (s) 10.0 6.6p 5.4
Basis images 288 300p 360
Exposure time per image 0.035 0.011 0.015
Exposure arc subtended per image 1.258 0.208 0.158
mAs 100.0 37.3 8.1
pThe i-CAT uses 2 scans (lower face, upper face) and interlaces the scans
to produce a full 1200 FOV CT volume. Smaller FOVs are produced with a
single scan
Figure 2 Lateral views demonstrating equivalent phantom positioning for 1200 field of view (FOV) examination: (A) CB Mercuray midsagittal
reconstruction, (B) NewTom 3G midsagittal reconstruction, (C) i-CAT midsagittal reconstruction
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the relative contribution of that organ or tissue to the overall
risk, and the radiation weighted dose HT.
13 The whole-body
risk is found by the summation of the radiation weighted
doses to all tissues or organs exposed. Both current 1990
ICRP tissue weights and proposed 2005 weights found in
Table 4 were used to calculate effective dose.13,14
The 1990 weighting factors have been assigned to 12
organs or tissues and a group of remainder organs for
purposes of calculating total E. Of the individually
weighted tissues or organs only bone marrow, oesophagus,
thyroid, bone surface and skin doses were included in this
study. Of the ten organs making up the remainder category,
only brain and muscle were included. The other individual
or remainder organs are not directly exposed in the
protocols used in this study. While an assumption of no
dose may underestimate actual exposure to these organs,
the impact on total E is negligible. Proposed tissue weights
for 2005 increase the number of independently weighted
tissues by 2 and expand the number of remainder tissues to
14. Remainder tissues directly exposed in the full FOV
CBCT exam include adipose, connective tissue, lymphatic
nodes, muscle and extrathoracic airway.
Results
Average dosemeter readings after three CBCT exposure
cycles ranged from 2.5 mGy for the full FOV NewTom 3G
examination to 32.7 mGy for the full FOV CB Mercuray
examination made at 120 kV and 15 mA. These doses are
well above theminimumdetection threshold of 0.3 mGy for
the TLD 100 chips. Table 5 provides dosemeter values for
the repeated full FOV exam with the CB Mercuray using
120 kV and 15 mA exposure factors. Overall reproduci-
bility, within the limits of dosemeter error, is indicated by an
average dose difference of 2.5% between repeated exam-
inations. Radiation weighted dose HT and effective dose E
calculations for the standard full FOV exams for each of the
CBCTunits are seen in Table 6.E(ICRP1990) andE(ICRP2005 draft)
for the NewTom 3G were 44.5, 58.9; for the i-CAT 134.8,
193.4; and for the CB Mercuray 476.6, 557.6. As a relative
multiple of the NewTom 3G full FOV dose, the i-CAT
examination resulted in 1.5 times more dose while the CB
Mercuray required 11 times more dose as calculated using
E(ICRP1990) values. Dose multiples using E(ICRP2005 draft)
values were 3.3 for the i-CAT and 9.5 for the CBMercuray.
Comparisons of E(ICRP1990) and E(ICRP2005 draft) for different
size FOVs as a multiple of panoramic examinations and as a
percentage of annual per capita background dose from all
sources are seen in Table 7.
Discussion
Comparison of multiple CBCT units using the same human
dosimetry phantom has not previously been done. Utilizing
the same phantom in equivalent full FOV examinations
with currently available 900 and 1200 FOV units permits a
relative comparison of their dosimetric performance.
While some aspects of dosemeter site selection and
handling of fractionally irradiated tissues have been
addressed by prior studies, newly included adipose,
connective tissue, lymphatic nodes, muscle and extrathor-
acic airway tissues in the proposed ICRP 2005 tissue
weighting scheme have not previously been addressed in
the dental literature. This study took a simplistic and
arbitrary approach in placing the body proportion of these
tissues exposed in a full FOV CBCT exam at 5%. As the
distribution of these tissues in the body is non-uniform, the
5% figure may overestimate or underestimate the actual
proportion of each tissue in the X-ray field. It is expected
Table 3 Estimated percentage of tissue irradiated and thermolumines-






Mandible 1.3 13, 14, 17, 18
Calvaria 11.8 1, 3
Cervical spine 3.4 15
Thyroid 100 22, 23
Oesophagus 10 24
Skin 5 8, 9, 10, 16
Bone surfacea 16.5
Mandible 1.3 13, 14, 17, 18
Calvaria 11.8 1, 3
Cervical spine 3.4 15
Salivary glands 100
Parotid 100 11, 12
Submandibular 100 19, 20
Sub-lingual 100 21
Brainb 100 4, 5
Remainder
Brainc 100 4, 5
Adiposeb 5 11, 12, 19–21
Connective tissueb 5 11, 12, 19–21
Lymphatic nodesb 5 11, 12, 19–21
Muscleab 5 6, 7, 15, 21, 24
Extrathoracic airwayb 100 11, 12, 19–21
Pituitary 100 5
Eyes 100 6, 7, 8, 9
aBone surface dose ¼ bone marrow dose £ 4.64; bICRP 200514; cICRP
199013
Table 4 Tissue weighting factors for calculation of effective dose –
ICRP 199013 and 2005 draft recommendations14
Tissue 1990 wT 2005 wT










Bone surface 0.01 0.01
Brain remainder 0.01
Kidneys remainder 0.01
Salivary glands – 0.01
Skin 0.01 0.01
Remainder tissues 0.05a 0.10b
aAdrenals, brain, upper large intestine, small intestine, kidney, muscle,
pancreas, spleen, thymus, uterus; bAdipose tissue, adrenals, connective
tissue, extrathoracic airways, gall bladder, heart wall, lymphatic nodes,
muscle, pancreas, prostate, SI wall, spleen, thymus, and uterus/cervix
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that future studies may refine the numeric used in
calculating proportions of tissues in the head and neck
area as well as the best location for dosemeter placement
for measuring exposure. Despite the uncertainty of effect
of these definitional and experimental uncertainties on an
absolute measure of effective dose, the relative comparison
of dose between units is valid.
Reproducibility of the dosimetric technique utilized in
this study was affirmed by the 2.5% overall variation
between repeated CB Mercuray examinations. However,
there were significant deviations for specific dosemeter
locations. This was especially apparent in dosemeters
placed on the skin surface and dosemeters placed near the
caudal and cranial extremes of the X-ray field. In particular
the thyroid surface detector exposure varied 91% between
repeated examinations. The next largest variation occurred
with the dosemeter placed at the back of the neck. It was
felt that the small anterior–posterior position differences
between the two exposures coupled with a dosemeter
location at the posterior periphery of laterally directed
projections may have played a role in the reading
difference of 32%. Internally positioned TLDs are
constrained by pre-drilled holes that snugly accommodate
the TLD and its protective envelope. Surface TLDs were
taped in place. The actual position of the TLD in its
envelope could have varied by as much as a centimetre.
Just as the position of dosemeters at the edge of the X-ray
field can impact recorded exposure, position of the patient
can also have a significant impact on dose to critical
organs. As a critical peripheral organ, the position of the
thyroid can be manipulated by a number of strategies
including upward tipping of the chin and use of smaller
FOVs to reduce dose.
While full FOV doses from the dental CBCT units in this
study were 2–23% of the dose of comparable conventional
CT examinations reported in the literature,17 they were also
several to hundreds of times greater than single panoramic
image exposures. It is hoped that a CBCT examination
would not be substituted for a panoramic examination if a
panoramic image alone would be adequate. In the case of
orthodontic diagnosis, substitution of the CBCT for
panoramic and lateral and posterior–anterior (PA) cephalo-
metric images may be contemplated. Dose calculations
using ICRP 1990 tissue weights are 6.2 mSv for a direct
digital panoramic image11 and 3.4 mSv for 2 cephalometric
images.18 If the calculation of E is modified to include
salivary glands then the panoramic and cephalometric doses
Table 5 Dosimetry reproducibility: Mercuray CB Full field of view (FOV) – 120 kV, 15 mA
Phantom location TLD ID Scan 1 (mGy) Scan 2 (mGy) Percent variation 2 from 1
Calvarium anterior (2) 1 8.97 10.20 13%
Calvarium left (2) 2 9.93 10.70 7%
Calvarium posterior (2) 3 6.87 7.43 8%
Mid brain (2) 4 9.07 9.33 3%
Pituitary (3) 5 9.30 9.40 1%
Right orbit (4) 6 10.03 10.10 1%
Left orbit (4) 7 9.93 10.33 4%
Right lens of eye (3) 8 16.37 16.70 2%
Left lens of eye (3) 9 15.70 16.37 4%
Right cheek (5) 10 15.43 15.70 2%
Right parotid (6) 11 14.40 14.67 2%
Left parotid (6) 12 13.30 14.23 7%
Right ramus (6) 13 9.47 10.20 7%
Left ramus (6) 14 9.73 10.60 9%
Centre cervical spine (6) 15 9.60 10.83 12%
Left back of neck (7) 16 12.53 17.33 32%
Right mandible body (7) 17 9.37 10.27 9%
Left mandible body (7) 18 9.57 11.00 14%
Right submandibular gland (7) 19 10.70 11.53 7%
Left submandibular gland (7) 20 11.37 11.53 1%
Centre sublingual gland (7) 21 9.83 10.30 5%
Midline thyroid (9) 22 11.00 11.40 4%
Thyroid surface – left (9) 23 12.93 4.83 291%
Oesophagus (9) 24 6.30 6.13 23%
Average TLD dose 10.90 11.30 2.50%
Table 6 Radiation weighted dose§ HT (mSv) and effective dose E (mSv)
for full (<1200) field of view (FOV) exposures for 3 cone beam computed
tomography (CBCT) units
Organ or tissue NewTom 3G i-CAT CB Mercuray
Bone marrow 125 418 692
Thyroid 333 767 6333
Oesophagus 57 123 393
Skin 62 187 389
Bone surface 581 1941 3211
Salivary glands 956 3522 5467
Brainp 700 3583 3967
Remainder
Brain† 700 3583 3967
Adiposep 48 176 273
Connective tissuep 48 176 273
Lymphatic nodesp 48 176 273
Extrathoracic airwayp 760 3733 4813
Musclep† 48 176 273
Pituitary 733 4233 4000
Eyes 1017 5008 6208
Effective Dose† 44.7 134.8 476.6
Effective Dosep 58.9 193.4 557.6
pICRP 2005 draft14; †ICRP 199013; §Formerly know as Equivalent dose
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increase to 22 mSv and 6.8 mSv, respectively. The full FOV
NewTom 3G examination is between 2 (E(ICRP2005 draft)) and
4.5 (E(ICRP1990)) times these conventional exposures.
In comparison with conventional plain radiography, the
potential for obtaining substantial additional information
from a CBCT volume is tremendous. Even in obtaining the
“same” information as that derived from conventional
views, the clinician is freed from the constraints of
cephalometric orientation, the problems of geometric
distortion, and many of the challenges of separating
cephalometric landmarks from structure noise. In addition
new ways of observing the data (maximum intensity
projections, multiplanar reconstructions, rotations in 3D)
may provide diagnostic insights that were not here-to-fore
possible. While additional diagnostic information may be
available in the CBCT volume, the question that must be
asked is “will this additional information contribute to the
diagnosis, and will it have a positive impact on the
patient’s treatment?”
If the clinician does not obtain significantly better
diagnostic information for the patient where CBCT is
substituted for a conventional orthodontic imaging series,
how concerned should he/she be about the additional dose?
On one hand the NewTom 3G doses are 4–6 days of
equivalent per capita background dose. On the other hand
CB Mercuray doses are 48–56 days of background dose.
To provide further prospective, the 150 mSv associated
with the most common full mouth radiographic examin-
ation (FMX) (D speed film, round collimation) utilizes
about 3 times the dose of the NewTom 3G exam and about
one third of the dose of the CB Mercuray exam.19
However, it should be noted that current NCRP guidelines
for dentistry recommend rectangular collimation and E or
F speed X-ray detectors, which would reduce the FMX
dose by a factor of 6 or more.20
It is noteworthy that smaller FOV examinations are
associatedwith significant dose reductions. In the case of the
CB Mercuray, the 900 FOV examination was produced with
60% (E(ICRP1990)) to 75% (E(ICRP2005 draft)) of the dose of the
standard 1200 FOV exam, while the 600 FOV exam centred on
the maxilla required only a third (E(ICRP1990)) to half
(E(ICRP2005 draft)) of the full FOV dose. To the extent that a
smaller FOV can be used to supply the needed diagnostic
information this approach should be used. A common
example of this would be the utilization of CBCT for implant
treatment planning. A single jaw is readily imaged by a 600
FOV and both jaws are completely visualized by a 900 FOV.
It is not enough to simply compare doses of alternate
imaging modalities. Issues of diagnostic quality cannot be
divorced from issues of dose. This study did not address
image quality. Exposure factors set by or recommended by
the manufacturer were used for standard exposures. In the
case of the CB Mercuray, which has user adjustable
technique factors, the maximum technique combination
was used to determine an upper limit of exposure from this
unit. In comparing subjectively the quality of images
produced with 120 kV and 15 mA with those produced by
100 kV and 10 mA, little difference could be seen. The
lower dose images were slightly noisier. Comparing
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3G images produced the same impression. While the CB
Mercuray images were less noisy, it was subjectively
similar in quality to the other units. Objective studies of the
effect of CBCT image quality on diagnostic performance
need to be conducted before definitive conclusions can be
made about the importance of the subjective differences in
image quality resulting from reduced exposure.
Examining the technical characteristics of the three
CBCT units in Table 2 shows that the principal factor
accounting for differences in dose in full FOV examinations
is mAs. While the NewTom 3G scans patients over a 36 s
period, exposure takes place for only 5.4 s. Similarly, the
i-CAT 900 FOV scans over a 20 s interval but the X-ray tube
is activated for only 3.3 s. The i-CAT implementation of a
nominal 1200 FOV is termed an “extended field of view” and
involves two 900 FOV scans, made sequentially and stitched
together to form a larger volume. Use of this double scan
technique preserves the resolution of the 900 scan, but
requires almost twice the exposure time and twice the
exposure. The CB Mercuray scans for about 11 s while the
tube produces X-rays for 10.0 s. While the CB Mercuray
exposes continuously, the NewTom 3G and i-CAT pulse
radiation. This results in amore efficient use of dose because
the detector is only being exposed while it is recording
photons. During periods when the detector is transferring its
image signal to the computer, radiation is turned off.
Another factor of potential importance is the sensitivity of
the detector. The i-CAT utilizes an amorphous silicon flat
panel detector while the NewTom 3G and the CBMercuray
incorporate an image intensifier and charge coupled device
(CCD) detector. Although differences in the sensitivity of
the X-ray detectors could play a role in dose efficiency it is
unknown what role, if any, this factor played in the
differences in dosimetry observed in this study.
The approach taken by each CBCT unit in setting
exposure factors is quite different. The simplest method is
used by the i-CAT where kV, mA, and exposure time are
established by the manufacturer and do not vary from
patient to patient. This technique requires that the dose be
sufficient to accommodate both large and small patients.
For smaller patients, such as children, this may produce
higher doses than required for diagnostic quality. The
NewTom 3G exposure is also fixed by the manufacturer.
However, a dynamic process is used where the quantity of
radiation required for a particular patient is determined
from PA and lateral scout views and the mA of the unit is
adjusted accordingly during the exposure. It is likely that
the small adult phantom used in this study resulted in a
lower dose with the NewTom 3G than would be seen with a
larger phantom or patient. With the CB Mercuray, the
operator sets factors of mA and kV. CBCT images provide
little feedback to indicate excessive exposure. After
window and levelling, overexposed images look good
and if anything are less noisy than properly exposed
volumes. Among inexperienced operators there may be a
tendency to maximize kV and mA settings. Images always
appear adequately exposed and noise is minimized by this
approach. With the majority of CBCT installations
currently taking place in orthodontic offices, the risk of
overexposure from the user adjustment technique is great.
The principal reason for revising tissueweighting factors
in the proposed 2005 ICRP draft document is the
availability of cancer incidence data that was not available
when the 1990 guidelines were published. ICRP 1990
cancer risks were computed based on mortality data.
Incidence data provide a more complete description of
cancer burden than do mortality data, particularly for
cancers that have a high survival rate. Much of the cancer
incidence data comes from the Life Span Study (LSS) of
Japanese atomic bomb survivors which has been updated
with follow-up through 1998, and has been corrected using
DS86 bomb dosimetry. Weighted tissues and organs were
selected in the 2005 revision because of sufficient
epidemiological information on the tumorigenic effects of
radiation to make judgments necessary for estimating
cancer risks. Changes include an increase in the detriment
of thyroid cancer to 0.05 due to the concentration of cancer
risk in childhood. Cancer risk in salivary glands, brain and
kidney were judged to be greater than that of other tissues in
the remainder fraction and each is ascribed a wT of 0.01. A
wT value for the remainder tissues of 0.1, distributed equally
amongst 14 named tissues, provides a weight of approxi-
mately 0.007 each, which is lower than thewT for the lowest
of the named tissues.14
The general increase in E(ICRP2005 draft) from E(ICRP1990)
calculations seen in this study is largely due to the inclusion
of salivary glands as a weighted tissue in E(ICRP2005 draft)
calculations. Moving brain from the remainder group with
provision of an independent weight of 0.01 contributes to a
lesser extent to the increase.While calculated E(ICRP2005 draft)
doses indicate a greater detriment from diagnostic imaging
relative to per capita background dose, detriment as a
function of multiples of panoramic images has actually
decreased (Table 7). The reason for this is that the locations
of the posterior rotational centres for panoramic scanning
motions are located near the parotid and submandibular
glandswhile the anterior rotational centre is located near the
sublingual gland. The salivary glands receive almost
continuous direct exposure during a panoramic examination
and thus absorb a disproportionately larger dose of
radiation. CBCT examinations result in a much more
uniform exposure of maxillofacial tissues.
The potential of significantly improved diagnostic
protocols and the long-term benefit of improved patient
care easily justify additional increments of small risk. The
results of this study do not provide a uniform picture about
the risks involved with current full FOV CBCT examin-
ations. Much additional work remains to be done. The
benefits of specific examination protocols need to be
validated with controlled prospective studies. In the
absence of such validation, practitioners need to apply
the skill, care, and judgment that sets them apart as
healthcare professionals in determining when and what
examination is indicated. When possible mA and kV
should be adjusted to minimize dose. The utilized dose
should be tailored to the diagnostic task with thoughtful
choice of FOV, and careful orientation of anatomy within
the field of view. CBCT technology continues to evolve
and new or improved units will appear in the marketplace
in the future. Both image quality and dosimetry
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information is needed on these units so that buyers can
make informed choices about the appropriateness of a
particular unit for their diagnostic needs. CBCT dose
varies substantially depending on the device, FOV and
selected technique factors. Full FOV examination i-CAT
doses were 3 (E(ICRP1990)) to 3.3 (E(ICRP2005 draft)) times
greater than NewTom 3G doses while Mercuray doses
were 10.7 (E(ICRP1990)) to 9.5 (E(ICRP2005 draft)) times greater.
Effective dose detriment of currently available large FOV
CPCT units is several to many times higher than
conventional panoramic imaging and several to many
times lower than reported doses for conventional CT.
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